Analysts Offer Predictions for XBIO Q1 Earnings

Xenetic Biosciences Inc (NASDAQ:XBIO) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Xenetic Biosciences in a note issued to investors on Thursday, March 20th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.72) for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Xenetic Biosciences’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Xenetic Biosciences’ Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.84) EPS and Q4 2025 earnings at ($0.88) EPS.

Xenetic Biosciences Stock Down 0.9 %

Shares of NASDAQ XBIO opened at $3.37 on Friday. The company’s 50-day simple moving average is $3.98 and its 200-day simple moving average is $3.99. Xenetic Biosciences has a 52-week low of $2.78 and a 52-week high of $5.20. The firm has a market cap of $5.20 million, a price-to-earnings ratio of -1.27 and a beta of 2.17.

Xenetic Biosciences (NASDAQ:XBIO) last announced its earnings results on Tuesday, March 18th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.48). Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. The company had revenue of $0.65 million during the quarter, compared to analyst estimates of $0.18 million.

Institutional Trading of Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. LGT Group Foundation bought a new stake in Xenetic Biosciences Inc (NASDAQ:XBIO) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned 0.71% of Xenetic Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.